secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001213900-24-027998
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing
--------------------------------------------------------------------------------

- Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.
- Gross license royalties $4.5M under Mayne License; net recognized $1.3M revenue and $0.5M other income.
- Operating expenses fell 85.4% to $9.8M, reflecting transition from commercial pharma to royalty model.
- Cash and equivalents $4.3M at Dec 31, 2023; company continues exploring strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/0001213900-24-027998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/ea0202833-8k_therape.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-027998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer